The Ghrelin agonist rm-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages 1453-1459.e4

  Shin, Andrea ^a   Camilleri, Michael ^a   Busciglio, Irene ^a   Burton, Duane ^a   Smith, Steven A ^b   Vella, Adrian ^b   Ryks, Michael ^a   Rhoten, Deborah ^a   Zinsmeister, Alan R ^b  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Clinical Trial; Drug; Gastroparesis; Prokinetic

Indexed keywords

GASTROINTESTINAL AGENT; GHRELIN; GLUCOSE; HEMOGLOBIN A1C; RM 131; UNCLASSIFIED DRUG;

ABDOMINAL SCINTISCANNING; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC FULLNESS; FEMALE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; SCINTIGRAPHY; STOMACH EMPTYING; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ADVERSE EVENT; AE; CF6; CLINICAL RESEARCH UNIT; CLINICAL TRIAL; COLONIC FILLING AT 6 HOURS; CRU; DAILY DIARY OF GASTROPARESIS CARDINAL SYMPTOM INDEX; DELAYED GASTRIC EMPTYING; DGE; DRUG; GASTRIC EMPTYING; GASTROINTESTINAL; GASTROPARESIS; GCSI-DD; GE; GI; INTERQUARTILE RANGE; IQR; NAUSEA, VOMITING FULLNESS, PAIN; NVFP; PROKINETIC; T(1/2); T1DM; T2DM; THE CALCULATED TIME POINT AT WHICH 50% OF THE RADIOLABELED MEAL HAS EMPTIED FROM THE STOMACH; TYPE 1 DIABETES MELLITUS; TYPE 2 DIABETES MELLITUS;

ADULT; AGED; ANIMALS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL TRACT; GASTROPARESIS; GHRELIN; HUMANS; MALE; MIDDLE AGED; RADIONUCLIDE IMAGING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885834009     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.019     Document Type: Article

References (26)

1. Camilleri M., Bharucha A.E., Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin Gastroenterol Hepatol 2011, 9:5-12.
2. Camilleri M., Parkman H.P., Shafi M.A., et al. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013, 108:18-37.
3. Soykan I., Sivri B., Sarosiek I., et al. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998, 43:2398-2404.
4. Choung R.S., Locke G.R., Schleck C.D., et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012, 107:82-88.
5. Jung H.K., Choung R.S., Locke G.R., et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009, 136:1225-1233.
6. Talley N.J., Young L., Bytzer P., et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol 2001, 96:71-76.
7. Hyett B., Martinez F.J., Gill B.M., et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 2009, 137:445-452.
8. Sanger G.J., Westaway S.M., Barnes A.A., et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009, 21:657-664. e30-1.
9. Takahashi N., Koba N., Yamamoto T., et al. W1390 characterization of a novel, potent, and selective small molecule motilin receptor agonist, RQ-00201894. Gastroenterology 2010, 138. S-713.
10. Ejskjaer N., Vestergaard E.T., Hellstrom P.M., et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009, 29:1179-1187.
11. Wo J.M., Ejskjaer N., Hellstrom P.M., et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting-randomised clinical study subset data. Aliment Pharmacol Ther 2011, 33:679-688.
12. Ejskjaer N., Wo J.M., Esfandyari T., et al. Aphase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013, 25:e140-e150.
13. Camilleri M., Papathanasopoulos A., Odunsi S.T. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2009, 6:343-352.
14. Murray C.D., Martin N.M., Patterson M., et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005, 54:1693-1698.
15. Shin A., Camilleri M., Busciglio I., et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013, 36:41-48.
16. Tougas G., Eaker E.Y., Abell T.L., et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000, 95:1456-1462.
17. Vazquez Roque M.I., Camilleri M., Stephens D.A., et al. Gastric sensorimotor functions and hormone profile in normal weight, overweight, and obese people. Gastroenterology 2006, 131:1717-1724.
18. Revicki D.A., Camilleri M., Kuo B., et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment Pharmacol Ther 2009, 30:670-680.
19. Revicki D.A., Camilleri M., Kuo B., et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012, 24:456-463. e215-6.
20. Camilleri M., Iturrino J., Bharucha A.E., et al. Performance characteristics of scintigraphic measurement of gastric emptying of solids in healthy participants. Neurogastroenterol Motil 2012, 24. 1076-e562.
21. Hochberg Y. Asharper Bonferroni procedure for multiple significance testing. Biometrika 1988, 75:800-802.
22. Bochicchio G., Charlton P., Pezzullo J.C., et al. Ghrelin agonist TZP-101/ulimorelin accelerates gastrointestinal recovery independently of opioid use and surgery type: covariate analysis of phase 2 data. World J Surg 2012, 36:39-45.
23. Ejskjaer N., Dimcevski G., Wo J., et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010, 22. 1069-e281.
24. Mearin F., Balboa A., Zárate N., et al. Placebo in functional dyspepsia: symptomatic, gastrointestinal motor, and gastric sensorial responses. Am J Gastroenterol 1999, 94:116-125.
25. Tack J., Depoortere I., Bisschops R., et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006, 55:327-333.
26. Rayner C.K., Su Y.C., Doran S.M., et al. The stimulation of antral motility by erythromycin is attenuated by hyperglycemia. Am J Gastroenterol 2000, 95:2233-2241.